Error loading player: No playable sources found
5115
IBD Controlled Trials II
Date
May 21, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented.
Moderators
Cleveland Clinic
UNC Chapel Hill
Tracks
Related Products
IBD Diagnosis. Monitoring, and Prediction of Complications
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD…
IBD Controlled Trials I
SOCIETY: AGA
Epi II: Best of Observational Studies in IBD
SOCIETY: AGA This session highlights the best of the best observational studies in IBD for DDW 2024 and provides clinical relevant and novel insights across the age and clinical spectrum, including wound healing after C-section…
Role of the Environment in IBD
SOCIETY: AGA As our scientific tools improve, so does our ability to link the environment with different aspects of IBD…
